Sinopharm Group 

$1.97
44
+$0+0% Wednesday 20:00

統計

當日最高
2.5
當日最低
2.5
52週最高
2.95
52週最低
1.97
成交量
200
平均成交量
1,848
市值
3.62B
市盈率
0
股息收益率
6.22%
股息
0.12

即將到來

股息

6.22%股息收益率
10年增長
11.23%
5年增長率
7.26%
3年增長率
4.23%
1年增長率
6.35%

收益

25Aug預期
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
0.69
1.04
1.4
1.75
預期每股收益
1.4800067469359999
實際每股收益
1.2762377020679998

人們還關注

此列表基於在 Stock Events 上關注 SHTDF 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Medical Distributors
Distribution Services
Health Technology
Pharmaceuticals: Major
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Show more...
首席執行官
員工
115959
國家
CN
ISIN
CNE100000FN7

上市公司